Linus Health, a Boston-based digital health company, will present new research findings on its AI-driven cognitive assessment tools at the upcoming AD/PD™ 2025 conference in Vienna, Austria, from April 1-5. The presentations will showcase the company's innovative approaches to early detection of cognitive and motor impairments in neurodegenerative diseases.
The 40th annual AD/PD conference brings together over 4,700 healthcare professionals, researchers, and industry experts from more than 70 countries to explore the mechanisms, prevention, and treatment of Alzheimer's and Parkinson's diseases in a unified setting.
Digital Tools for Parkinson's Disease Assessment
Dr. Ali Jannati, Director of Cognitive Science at Linus Health, will present findings demonstrating that the company's DCTclock™ technology effectively detects cognitive impairment in Parkinson's disease (PD) patients and can differentiate between varying levels of cognitive function.
The study revealed that DCTclock's Oscillatory Motion (OM) metric accurately quantifies drawing tremors and correlates strongly with clinician ratings. These results position DCTclock as a valuable tool for assessing both cognitive and motor impairments in PD patients, particularly for tremor detection.
"Our digital assessment tools provide clinicians with sensitive metrics that can detect subtle changes in cognitive and motor function that might otherwise go unnoticed in routine examinations," explained Dr. Jannati.
Rapid Digital Cognitive Assessment Validated
In a second presentation, Dr. Jannati will share validation data for Linus Health's 7-minute Digital Assessment of Cognition (DAC). This innovative tool, which analyzes patient speech responses, demonstrated high accuracy in classifying cognitive status when compared to traditional neuropsychological evaluations that typically take three hours to complete.
The researchers concluded that the DAC offers a rapid, scalable solution for cognitive evaluation that can be administered either remotely or in-person. This technology has the potential to significantly increase the efficiency of specialists' workflows while maintaining diagnostic accuracy.
"The ability to conduct comprehensive cognitive assessments in just seven minutes represents a paradigm shift in how we approach brain health screening," said Dr. Jannati. "These findings highlight the value of our solutions for clinicians, researchers, and patients."
Expanding Presence in Life Sciences
Linus Health has been experiencing significant growth in the life sciences sector, with its digital assessment platform now being utilized by many of the world's largest pharmaceutical companies for clinical trials in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS), as well as mental health conditions like depression and schizophrenia.
The company's 2024 acquisition of Aural Analytics has further expanded its capabilities, adding the AI-driven Speech Vitals analytics solution to its portfolio of over 30 digital assessments. This expansion reflects the growing recognition of digital biomarkers as valuable tools in neurodegenerative disease research.
David Bates, PhD, CEO and co-founder of Linus Health, emphasized the company's impact on clinical trial efficiency: "Linus Health is working with more pharma and life sciences companies than ever before because we help solve their most pressing challenge: increasing clinical trial efficiency and success while maintaining scientific rigor and capturing meaningful results."
Accelerating Clinical Trials
The company's digital solutions address several critical challenges in clinical trial recruitment and assessment. Traditional recruitment methods are often slow, expensive, and plagued by high screening failure rates. Linus Health's remote and in-clinic assessments enable more efficient pre-screening, helping clinical sites identify and enroll suitable participants more quickly and confidently.
Additionally, the sensitivity of the AI-based technology strengthens outcome measurements, allowing researchers to more accurately assess the impact of novel treatments. Beyond clinical trials, Linus Health supports post-market studies in real-world clinical settings to monitor the safety, efficacy, and long-term benefits of new therapies.
The company's approach is backed by an extensive library of 145 published peer-reviewed studies, demonstrating its commitment to scientific validation and evidence-based practice.
Bridging Research and Clinical Practice
Linus Health's platform represents a significant advancement in the early detection and monitoring of neurodegenerative diseases. By combining cutting-edge neuroscience, clinical expertise, and artificial intelligence, the company aims to transform brain health assessment and enable more proactive intervention.
Conference attendees can visit Linus Health at booth #79 to learn more about these research findings and how the company's solutions are being implemented in clinical trials and research settings worldwide.
As neurodegenerative diseases continue to pose significant healthcare challenges globally, digital assessment tools like those developed by Linus Health offer promising avenues for earlier detection, more precise monitoring, and potentially better outcomes for patients with conditions like Alzheimer's and Parkinson's disease.
